Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Tumor Necrosis Factor Receptor Superfamily Member 18 market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.2% during the forecast period.
This report presents the market size and development trends by detailing the Tumor Necrosis Factor Receptor Superfamily Member 18 market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Tumor Necrosis Factor Receptor Superfamily Member 18 market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Tumor Necrosis Factor Receptor Superfamily Member 18 industry and will help you to build a panoramic view of the industrial development.
Tumor Necrosis Factor Receptor Superfamily Member 18 Market, By Type:
AMG-228
BMS-986156
FPA-154
GWN-323
INCAGN-1876
Others
Tumor Necrosis Factor Receptor Superfamily Member 18 Market, By Application:
Melanoma
Non-Small Cell Lung Cancer
Gastric Cancer
Blood Cancer
Others
Some of the leading players are as follows:
MedImmune LLC
Bristol-Myers Squibb Company
Merck & Co Inc
OncoMed Pharmaceuticals Inc
Novartis AG
Amgen Inc
Apogenix GmbH
Ablynx NV
Five Prime Therapeutics Inc
Regeneron Pharmaceuticals Inc
Incyte Corp
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Tumor Necrosis Factor Receptor Superfamily Member 18 Market: Technology Type Analysis
-
4.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 AMG-228
4.3.2 BMS-986156
4.3.3 FPA-154
4.3.4 GWN-323
4.3.5 INCAGN-1876
4.3.6 Others
5 Tumor Necrosis Factor Receptor Superfamily Member 18 Market: Product Analysis
-
5.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Product Market Share Analysis, 2018 & 2026
-
5.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Tumor Necrosis Factor Receptor Superfamily Member 18 Market: Application Analysis
-
6.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Application Market Share Analysis, 2018 & 2026
-
6.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Melanoma
6.3.2 Non-Small Cell Lung Cancer
6.3.3 Gastric Cancer
6.3.4 Blood Cancer
6.3.5 Others
7 Tumor Necrosis Factor Receptor Superfamily Member 18 Market: Regional Analysis
-
7.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Regional Market Share Analysis, 2018 & 2026
-
7.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 MedImmune LLC
9.1.1 MedImmune LLC Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Bristol-Myers Squibb Company
9.2.1 Bristol-Myers Squibb Company Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Merck & Co Inc
9.3.1 Merck & Co Inc Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 OncoMed Pharmaceuticals Inc
9.4.1 OncoMed Pharmaceuticals Inc Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Novartis AG
9.5.1 Novartis AG Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Amgen Inc
9.6.1 Amgen Inc Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Apogenix GmbH
9.7.1 Apogenix GmbH Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Ablynx NV
9.8.1 Ablynx NV Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Five Prime Therapeutics Inc
9.9.1 Five Prime Therapeutics Inc Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Regeneron Pharmaceuticals Inc
9.10.1 Regeneron Pharmaceuticals Inc Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Incyte Corp
9.11.1 Incyte Corp Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
The List of Tables and Figures (Totals 86 Figures and 142 Tables)
Figure AMG-228 Tumor Necrosis Factor Receptor Superfamily Member 18 market, 2015 - 2026 (USD Million)
Figure BMS-986156 Tumor Necrosis Factor Receptor Superfamily Member 18 market, 2015 - 2026 (USD Million)
Figure FPA-154 Tumor Necrosis Factor Receptor Superfamily Member 18 market, 2015 - 2026 (USD Million)
Figure GWN-323 Tumor Necrosis Factor Receptor Superfamily Member 18 market, 2015 - 2026 (USD Million)
Figure INCAGN-1876 Tumor Necrosis Factor Receptor Superfamily Member 18 market, 2015 - 2026 (USD Million)
Figure Others Tumor Necrosis Factor Receptor Superfamily Member 18 market, 2015 - 2026 (USD Million)
Figure Melanoma market, 2015 - 2026 (USD Million)
Figure Non-Small Cell Lung Cancer market, 2015 - 2026 (USD Million)
Figure Gastric Cancer market, 2015 - 2026 (USD Million)
Figure Blood Cancer market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by country, 2015 - 2026 (USD Million)
-
Table North America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table North America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table North America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Canada Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Canada Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Europe Tumor Necrosis Factor Receptor Superfamily Member 18 market, by country, 2015 - 2026 (USD Million)
-
Table Europe Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Europe Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Europe Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Germany Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Germany Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table France Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table France Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Italy Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Italy Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Spain Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Spain Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table China Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table China Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Japan Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Japan Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table India Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table India Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table MEA Tumor Necrosis Factor Receptor Superfamily Member 18 market, by country, 2015 - 2026 (USD Million)
-
Table MEA Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table MEA Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table MEA Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Tumor Necrosis Factor Receptor Superfamily Member 18 market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Tumor Necrosis Factor Receptor Superfamily Member 18 market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Tumor Necrosis Factor Receptor Superfamily Member 18 market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table MedImmune LLC Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Company Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table OncoMed Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Apogenix GmbH Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ablynx NV Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Five Prime Therapeutics Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Regeneron Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Incyte Corp Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
